AURKB and prostate carcinoma: We further substantiated in LNCaP cells that the microtubule instability resulting from BRCA2 deficiency could be effectively reversed in prostate cancer cells by use of a specific chemical inhibitor of AURKB (Figure 6E and Supplemental Figure 6C).